{
  "OPTISAGE": {
    "AML": "acute myeloid leukemia",
    "MDS": "myelodysplastic",
    "RIC": "reduced intensity conditioning",
    "EFS": "event free survival",
    "GVL": "graft versus leukemia",
    "ATG": "Anti thymocyte globulins",
    "MUD": "matched unrelated donor",
    "GRFS": "GVHD relapse free survival",
    "MMF": "mycophenolate mofetil"
  },
  "CAALLF01": {
    "ALL": "acute lymphoblastic leukemia",
    "ASNase": "asparaginase",
    "DI": "delayed intensifications",
    "IM": "intramuscularly",
    "EU": "European Union",
    "UK": "UKALL",
    "MRD": "Minimal Residual Disease",
    "AE": "adverse events",
    "TLP": "traumatic lumbar puncture",
    "GPR": "Good prednisone response",
    "PPR": "Poor Prednisone response"
  },
  "HAPLO-EMPTY": {
    "SAA": "severe aplastic anemia",
    "MUD": "matched unrelated donor",
    "ELT": "eltrombopag",
    "PNH": "paroxysmal nocturnal hemoglobinuria",
    "MDS": "myelodysplastic",
    "AML": "acute myeloid leukemia",
    "HSCT": "Hematopoietic stem cell transplantation",
    "PTCy": "post transplantation cyclophosphamide",
    "GvHD": "Graft versus Host Disease",
    "OS": "overall survival"
  },
  "KAPVEC": {
    "KS": "Kaposi sarcoma",
    "MCC": "Merkel cell carcinoma",
    "BORR": "best overall response rate",
    "ANC": "Absolute neutrophil count",
    "ULN": "upper limit normal"
  },
  "FIBRAPLO": {
    "OS": "overall survival",
    "DFS": "disease free survival"
  },
  "SONIMEL": {
    "BBB": "Blood Brain Barrier",
    "US": "UltraSound",
    "MSD": "most successful dose",
    "PFS": "Progression free survival",
    "OS": "Overall survival",
    "ORR": "objective response rate",
    "ECOG": "Eastern Cooperative Oncology Group",
    "PS": "performance status"
  },
  "DREPA-RIC": {
    "SCD": "sickle cell disease",
    "HSCT": "hematopoietic stem cell transplantation",
    "MRD": "matched related donor",
    "GVHD": "graft versus host disease",
    "TBI": "total body irradiation",
    "CT": "computed tomography",
    "DHTR": "delayed hemolytic transfusion reaction",
    "HADS": "Hospital Anxiety Depression Scale",
    "TP": "transfusion program",
    "GFR": "glomerular fraction rate"
  },
  "PARADISE": {
    "PCC": "panenteric Crohn Capsule",
    "CDED": "Crohn Disease Exclusion Diet",
    "ITT": "intent to treat"
  },
  "MARVEL": {
    "DME": "drug metabolizing enzymes",
    "V": "venlafaxine",
    "ODV": "ODemethylV",
    "MAR": "missing at random"
  },
  "PIPAC": {
    "QoL": "quality of life",
    "CI": "Confidence Intervals"
  },
  "JAKAHDI": {
    "HS": "Hemophagocytic syndrome"
  },
  "GRAALL-2014/B": {
    "SR": "Standard risk",
    "HR": "high risk",
    "CIR": "cumulative incidence relapse",
    "NRM": "non relapse mortality",
    "DFS": "disease free survival",
    "OS": "overall survival",
    "CNS": "central nervous system",
    "HIV": "human immunodeficiency virus",
    "Blina": "blinatumomab",
    "SCT": "stem cell transplantation",
    "PO": "Prednisone",
    "SAEs": "Serious adverse events"
  },
  "METIMGAST": {
    "ORR": "overall response rate",
    "mAbs": "monoclonal antibodies",
    "HIV": "Human Immunodeficiency Virus",
    "CNS": "central nervous system",
    "SBP": "Systolic Blood Pressure",
    "DBP": "Diastolic Blood Pressure",
    "ULN": "Upper Limit Normal",
    "AST": "Aspartate",
    "PT": "Prothrombin Time",
    "INR": "International Normalized Ratio",
    "ANC": "Absolute neutrophil count",
    "cTnI": "Cardiac troponin"
  },
  "RUBI": {
    "BCVA": "best corrected visual acuity",
    "NIU": "Non infectious Uveitis",
    "IFN": "interferon",
    "TB": "Tuberculosis",
    "GFR": "Glomerular filtration rates",
    "NYHA": "New York Heart Association",
    "OCT": "ocular coherence tomography",
    "CME": "cystoid macular edema",
    "MAMS": "Multi Arm Multi Stage"
  },
  "MSC-AT-SSC": {
    "SSc": "Systemic sclerosis",
    "AD": "autoimmune disease",
    "AHSCT": "autologous hematopoietic stem cell transplantation",
    "MSC": "Mesenchymal stromal cells",
    "M": "MSC",
    "IV": "intravenous",
    "EFS": "Etablissement Français Sang",
    "AT": "after",
    "SAE": "Severe Adverse Events",
    "AE": "Adverse Events",
    "CTCAE": "Common Terminology Criteria Adverse Events",
    "PFS": "Progression free survival",
    "GRCS": "Global Rank Composite Score",
    "mRSS": "modified Rodnan Skin Score",
    "PS": "performance status",
    "HRQoL": "Health Related Quality of Life",
    "SHAQ": "Scleroderma Health Assessment Questionnaire",
    "FVC": "Forced Vital Capacity",
    "HRCT": "high resolution computed tomography",
    "TRSAE": "treatment related Severe Adverse Events",
    "DSMB": "Data Safety Monitoring Board"
  },
  "UVB": {
    "BCVA": "best corrected visual acuity",
    "AC": "anterior chamber",
    "VH": "vitreous haze",
    "BDCA": "Behcet Disease Current Activity",
    "BSAS": "BDCA s Activity Score",
    "QOL": "quality of life",
    "OCT": "Optical Coherence Tomography",
    "ICBD": "International Criteria Behçet Disease",
    "IGRA": "interferon gamma release assay",
    "NYHA": "New York Heart Association",
    "GFR": "Glomerular filtration rates"
  },
  "INTORETAK": {
    "TA": "Takayasu arteritis",
    "CS": "corticosteroids",
    "ACR": "American College Rheumatology",
    "NIH": "National Institute Health",
    "TST": "tuberculin skin test",
    "IGRA": "interferon gamma release assay",
    "HIV": "human immunodeficiency virus",
    "AST": "as shown transaminase"
  },
  "TRIBECA": {
    "W": "week",
    "HB": "Hepatitis B",
    "WCBP": "Women Child Bearing Potential"
  },
  "MSC-SLE": {
    "SLE": "Systemic Lupus Erythematosus",
    "AD": "and Disease",
    "MSC": "Mesenchymal Stem cells",
    "WHO": "World Health Organization",
    "MCR": "Major Clinical Response"
  },
  "PCL-2": {
    "pPCL": "Primary plasma cell leukemia",
    "OS": "overall survival",
    "MM": "multiple myeloma",
    "MRD": "minimal residual disease",
    "TEAE": "Treatment Emergent Adverse Event",
    "SAE": "Serious Adverse Event",
    "NCI": "National Cancer Institute",
    "TLS": "tumor lysis syndrome",
    "ECOG": "Eastern Cooperative Oncology Group",
    "ULN": "upper limit normal",
    "AST": "aspartate",
    "PCR": "polymerase chain reaction",
    "HBV": "hepatitis B virus",
    "CNS": "central nervous system",
    "GCP": "good clinical practice",
    "ICH": "International Conference Harmonization"
  },
  "ITAC": {
    "BD": "BD disease",
    "QOL": "quality of life",
    "MRI": "magnetic resonance imaging",
    "IGRA": "interferon gamma release assay"
  },
  "FOCUS": {
    "NIU": "non infectiuous uveitis",
    "BCVA": "best corrected visual acuity",
    "OCT": "optical coherence tomographic",
    "IGRA": "interferon gamma release assay",
    "GFR": "Glomerular filtration rates",
    "NYHA": "New York Heart Association"
  },
  "ICE": {
    "MC": "mixed cryoglobulinaemia",
    "MGUS": "myeloma gammapathy unknown significance",
    "W": "week",
    "BVAS": "Birmingham Vasculitis Activity Score"
  },
  "MAC-HAPLO-MUD": {
    "SCT": "stem cell transplantation",
    "MUD": "matched unrelated donors",
    "CNI": "calcineurin",
    "GvHD": "graft versus host disease",
    "PBSC": "Peripheral blood stem cell",
    "HR": "Hazard ratio"
  },
  "SHORTCUT": {
    "KTR": "kidney transplant recipients",
    "UTI": "urinary tract infection",
    "MDR": "Multidrug",
    "APN": "acute pyelonephritis"
  },
  "CAMOVID": {
    "RTPCR": "reverse transcription polymerase chain reaction",
    "S": "spike",
    "AEs": "Adverse events",
    "SAEs": "serious AEs",
    "GPs": "general practitioners",
    "GHSIF": "Groupe Hospitalier Sud Ile France"
  },
  "GREEN": {
    "AIS": "acute ischemic stroke",
    "SAEs": "serious adverse events",
    "SUSARs": "suspected unexpected serious adverse reactions",
    "BREs": "bleeding related events",
    "TEAEs": "Treatment Emergent Adverse Events",
    "ADA": "at days Anti",
    "LVO": "large vessel occlusion",
    "ICA": "internal carotid artery",
    "MRA": "magnetic resonance angiography",
    "WOCBP": "Women of child bearing potential",
    "DAPT": "dual anti platelet therapy"
  },
  "TEOREM": {
    "CD": "Crohn disease",
    "AIEC": "adherent invasive E coli",
    "SSR": "Sample size re"
  },
  "SALMA": {
    "AML": "Acute Myeloid Leukemias",
    "SOC": "standard of care",
    "HSCT": "hematopoietic stem cell transplantation",
    "IDA": "idarubicin",
    "CR": "complete remission",
    "ED": "early date",
    "EFS": "event free survival",
    "MFC": "multiparameter flow cytometry",
    "MRD": "Measurable Residual Disease",
    "EOI": "end of induction",
    "LSCs": "Leukemic Stem Cells",
    "ROS": "Reactive Oxygen Species",
    "CpG": "Carboxyphenylglycine",
    "SSZ": "sulfasalazine",
    "PDX": "patient derived xenografts",
    "DNR": "daunorubicin",
    "DLTs": "dose limiting toxicities",
    "MTD": "maximal tolerated dose",
    "DLT": "dose limiting toxicity",
    "PK": "pharmacokinetics",
    "PD": "pharmacodynamics",
    "AE": "Adverse events",
    "TEAE": "treatment emergent adverse events",
    "SAEs": "serious adverse events",
    "Cmax": "Corporation maximum",
    "Cl": "clearance",
    "MRT": "mean residence time",
    "MDA": "malondialdehyde",
    "MLFS": "Morphologic leukemia free state",
    "PR": "Partial response",
    "ORR": "Overall response rate",
    "DOR": "Duration of response",
    "RFS": "Relapse free survival",
    "OS": "Overall survival",
    "DSMB": "data safety monitoring board",
    "MDS": "Myelodysplastic",
    "ULN": "upper limit normal",
    "GFR": "glomerular filtration rate",
    "HIV": "human immunodeficiency virus",
    "DL": "dose levels",
    "CRM": "continual reassessment method"
  },
  "ERYTHROSIM": {
    "PRCA": "pure red cell aplasia"
  },
  "EFRAIM-II": {
    "ARF": "Acute respiratory failure",
    "DNI": "Do Not Intubate",
    "DNR": "Do Not Resuscitate"
  },
  "RECORDS": {
    "CS": "corticosteroids",
    "ICU": "intensive care unit"
  },
  "KAPKEY": {
    "KS": "Kaposi s",
    "BORR": "Best Overall Response Rate",
    "CTCAE": "Common Terminology Criteria Adverse Events",
    "ANC": "Absolute neutrophil count",
    "mAb": "monoclonal antibody"
  },
  "UPFRONT-MUD": {
    "AA": "aplastic anemia",
    "FFS": "failure free survival",
    "MUD": "matched unrelated donor",
    "HSCT": "hematopoietic stem cell transplantation",
    "GvHD": "Graft versus Host Disease",
    "MTX": "methotrexate"
  },
  "HAPLORESCUE": {
    "CNI": "calcineurin",
    "DSA": "donor specific antibody"
  },
  "FIRST": {
    "HMA": "hypomethylating",
    "OS": "Overall Survival",
    "DFS": "disease free survival",
    "NRM": "Non relapse mortality",
    "DSA": "donor specific antibody",
    "BMI": "Body Mass Index",
    "PBSC": "peripheral blood stem cell",
    "MMF": "mycophenolate mofétil",
    "CR": "complete remission"
  },
  "APARR": {
    "HSCT": "Hematopoietic Stem Cell Transplantation",
    "AA": "acquired aplastic",
    "EPAG": "eltrombopag",
    "PNH": "paroxysmal nocturnal hemoglobinuria",
    "MDS": "myelodysplastic",
    "AML": "acute myeloid leukemia",
    "PTCy": "post transplantation cyclophosphamide",
    "GvHD": "graft versus host disease"
  }
}